Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Genfit SA ( (GNFT) ).
On May 14, 2025, GENFIT announced the publication of its 2025 Extra-Financial Performance Report, reflecting its ongoing commitment to social and environmental responsibility. The report highlights the company’s progress in 2024, including increased patient engagement, educational initiatives, and gender equality assessments. GENFIT’s approach to ESG has been integral to its strategy, aiming to maximize positive impacts and manage risks. The company’s efforts in sustainable development and corporate social responsibility are seen as enhancing trust with stakeholders and contributing to its long-term growth.
The most recent analyst rating on (GNFT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score of 59 reflects a blend of significant financial recovery and positive technical momentum, indicating a promising direction for the company. However, the high P/E ratio suggests that the stock may be overvalued, which is a key risk factor. While the financial performance shows improvement, the need for better operational efficiency and more balanced capital structure remain areas for improvement to support long-term growth.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a late-stage biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases, particularly Acute-on-Chronic Liver Failure (ACLF). The company has a diverse R&D portfolio and is known for its expertise in liver disease research, with assets targeting diseases like cholangiocarcinoma and urea cycle disorder. GENFIT is headquartered in Lille, France, and is listed on the Nasdaq and Euronext markets.
Average Trading Volume: 14,436
Technical Sentiment Signal: Buy
Current Market Cap: $217.5M
See more insights into GNFT stock on TipRanks’ Stock Analysis page.